phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patients
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Panitumumab+CPT-11 repeat every 14 days until discontinuance criteria. Primary outcome(s): Response Rate:RR Study Design: Single arm Non-randomized
创建时间：
2011-02-15
